Mrv1909 01262017112D 18 20 0 0 0 0 999 V2000 -0.8962 -0.9655 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 -0.8962 -1.7906 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 -1.5975 -2.2032 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 -2.3401 -1.7906 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 -2.3401 -0.9655 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 -1.5975 -0.5530 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 -0.1123 -0.7180 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 0.3827 -1.3781 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 -0.1123 -2.0381 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0 -1.5975 0.2720 0.0000 C 0 0 2 0 0 0 0 0 0 0 0 0 -2.0099 0.9734 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 -1.1849 0.9734 0.0000 C 0 0 1 0 0 0 0 0 0 0 0 0 -0.4687 1.3831 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 0.2316 0.9748 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0 0.9367 1.3780 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 1.6330 0.9723 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 0.9367 2.2031 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0 2.3401 1.3769 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 1 2 2 0 0 0 0 2 3 1 0 0 0 0 3 4 2 0 0 0 0 4 5 1 0 0 0 0 5 6 2 0 0 0 0 1 6 1 0 0 0 0 1 7 1 0 0 0 0 7 8 1 0 0 0 0 8 9 1 0 0 0 0 2 9 1 0 0 0 0 10 6 1 6 0 0 0 11 12 1 0 0 0 0 11 10 1 0 0 0 0 12 10 1 0 0 0 0 12 13 1 1 0 0 0 13 14 1 0 0 0 0 14 15 1 0 0 0 0 15 16 1 0 0 0 0 15 17 2 0 0 0 0 16 18 1 0 0 0 0 M END > DB09071 > drugbank > CCC(=O)NC[C@@H]1C[C@H]1C1=CC=CC2=C1CCO2 > InChI=1S/C15H19NO2/c1-2-15(17)16-9-10-8-13(10)11-4-3-5-14-12(11)6-7-18-14/h3-5,10,13H,2,6-9H2,1H3,(H,16,17)/t10-,13+/m0/s1 > PTOIAAWZLUQTIO-GXFFZTMASA-N > C15H19NO2 > 245.322 > 245.141578856 > 2 > 37 > 0.05966247600853131 > 27.515584969904353 > 1 > 1 > 0 > 1 > N-{[(1R,2R)-2-(2,3-dihydro-1-benzofuran-4-yl)cyclopropyl]methyl}propanamide > 2.53 > 1.9775411676666674 > -3.81 > 0 > 0 > 3 > 0 > 15.739439078225127 > -1.1975952704927078 > 38.33 > 70.3479 > 4 > 1 > 3.81e-02 g/l > tasimelteon > 1 > DB09071 > DB05359 > approved; investigational > Tasimelteon > N-{[(1R,2R)-2-(2,3-dihydro-1-benzofuran-4-yl)cyclopropyl]methyl}propanamide; Tasimeltéon; Tasimelteon; Tasimelteón; Tasimelteonum > Hetlioz; Hetlioz LQ; Tasimelteon > Hetlioz $$$$